Cargando…

Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry

BACKGROUND: P2Y12 antagonist therapy improves outcomes in acute myocardial infarction (MI) patients. Novel agents in this class are now available in the US. We studied the introduction of prasugrel into contemporary MI practice to understand the appropriateness of its use and assess for changes in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sherwood, Matthew W., Wiviott, Stephen D., Peng, S. Andrew, Roe, Matthew T., DeLemos, James, Peterson, Eric D., Wang, Tracy Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187510/ https://www.ncbi.nlm.nih.gov/pubmed/24732921 http://dx.doi.org/10.1161/JAHA.114.000849

Ejemplares similares

European NSTEMI guidelines—return of clopidogrel?
por: Dannenberg, Lisa, et al.
Publicado: (2021)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

Analysis of STEMI and NSTEMI in a Community Cohort of Marijuana Users
por: Jean-Louis, Farla, et al.
Publicado: (2022)

Comparison of Clopidogrel With Prasugrel and Ticagrelor in Patients With Acute Coronary Syndrome: Clinical Outcomes From the National Cardiovascular Database ACTION Registry
por: Khayata, Mohamed, et al.
Publicado: (2017)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Late STEMI and NSTEMI Patients’ Emergency Calling in COVID-19 Outbreak
por: Trabattoni, Daniela, et al.
Publicado: (2020)

Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

Health-Related Quality-of-Life after Percutaneous Coronary Intervention in Patients with UA/NSTEMI and STEMI: the Korean Multicenter Registry
por: Kim, Mi-Jeong, et al.
Publicado: (2013)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Predictors of Long-Term Outcome in STEMI and NSTEMI—Insights from J-MINUET
por: Lechner, Ivan, et al.
Publicado: (2020)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
por: Wang, Zhe, et al.
Publicado: (2020)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
por: Lee, Dongwhane, et al.
Publicado: (2018)

Association of the genetic and traditional risk factors of ischaemic heart disease with STEMI and NSTEMI development
por: Žaliaduonytė-Pekšienė, Diana, et al.
Publicado: (2017)

Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome
por: Charach, Lior, et al.
Publicado: (2021)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry
por: Mori, Hiroyoshi, et al.
Publicado: (2022)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Synthesized 18-Lead Electrocardiogram in Diagnosing Posterior Stemi-Equivalent Acute Coronary Syndrome in Patients with NSTEMI
por: Horie, Tomoki, et al.
Publicado: (2022)

Hospital admissions and mortality for STEMI and NSTEMI during COVID-19 outbreak: a meta-analysis: Paolo Matteo Angeletti
por: Altobelli, E, et al.
Publicado: (2022)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Rescue PCI in the management of STEMI: Contemporary results from the Melbourne Interventional Group registry()
por: Fernando, Himawan, et al.
Publicado: (2021)

Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI)
por: Chorell, Elin, et al.
Publicado: (2020)

Shock index and modified shock index are predictors of long-term mortality not only in STEMI but also in NSTEMI patients
por: Schmitz, Timo, et al.
Publicado: (2022)

Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarction
por: Takeji, Yasuaki, et al.
Publicado: (2021)

DID THE COVID-19 PANDEMIC CAUSE PATIENTS WITH TYPE I STEMI OR NSTEMI TO DELAY SEEKING MEDICAL ATTENTION?
por: Wagle, Sugat, et al.
Publicado: (2022)

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry
por: Goldstein, Patrick, et al.
Publicado: (2016)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
por: Olechowski, Bartosz, et al.
Publicado: (2016)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis
por: Guan, Baoyi, et al.
Publicado: (2022)

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
por: Nadarajah, Ramesh, et al.
Publicado: (2023)

Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy
por: Lee, Dong Hyun, et al.
Publicado: (2014)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
por: Lee, Dongwhane, et al.
Publicado: (2019)

De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early?
por: Masiero, Giulia, et al.
Publicado: (2020)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
por: Rezaei, Safoura Sheikh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n4e4tt03qpn9bma3j0vvf1c50b